The Biotech Bi-Weekly: Unveiling a New Brain Organoid Assay, Advancing Epigenomics Research and Building an Infectious Disease Research Portfolio

Key Takeaways

• 28bio launches CNS‑3D organoid assay for Alzheimer drug testing
• Sino Biological releases XPressMAX kit for AI‑driven antibody screening
• Araceli launches Endeavor Live Cell for rapid kinetic imaging on 1536‑well plates
• EpiCypher and NEB expand partnership to co‑develop next‑gen epigenomics tools
• Lilly acquires Curevo, LimmaTech, Vaccine Co. to boost infectious disease pipeline

Pulse Analysis

The launch of 28bio’s CNS‑3D Induced Alzheimer’s Model marks a notable advance in neurodegenerative research. By integrating human neuroimmune organoids with exogenous amyloid‑beta oligomers, the assay reproduces key hallmarks of Alzheimer’s, including tau pathology and neuronal network dysfunction. Researchers can now evaluate candidate therapeutics in a physiologically relevant 3‑D environment, shortening the gap between preclinical studies and clinical trials and potentially lowering attrition rates for brain‑targeted drugs.

Parallel innovations from Sino Biological and Araceli Biosciences are reshaping high‑throughput screening. Sino’s XPressMAX cell‑free protein synthesis kit fuels AI‑driven antibody discovery pipelines, delivering rapid protein expression without cell culture bottlenecks. Araceli’s Endeavor® Live Cell system extends ultra‑high‑throughput imaging to kinetic readouts across entire 1536‑well plates, enabling lab‑in‑the‑loop workflows where real‑time cellular dynamics inform machine‑learning models. Together, these tools accelerate the iterative cycle of design, test, and optimization that underpins modern drug development.

Strategic collaborations and acquisitions underscore the industry’s focus on expanding therapeutic horizons. The expanded EpiCypher‑New England Biolabs partnership promises next‑generation epigenomics platforms that will deepen insight into gene regulation and disease mechanisms. Meanwhile, Eli Lilly’s purchase of Curevo, LimmaTech Biologics, and Vaccine Company bolsters its infectious‑disease portfolio, positioning the company to leverage differentiated vaccine and biologic technologies amid rising global health concerns. Collectively, these moves illustrate a concerted effort to integrate cutting‑edge biology with scalable platforms, driving both innovation and market growth in biotech.